Apyx Medical Corp
Form SC 13G/A
January 18, 2019

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

APYX MEDICAL CORPORATION

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

03837C106

(CUSIP Number)

December 31, 2018

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1.   NAMES OF REPORTING PERSONS

      William Weeks Vanderfelt

2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

      (a)   (b)

3.   SEC USE ONLY

4.   CITIZENSHIP OR PLACE OF ORGANIZATION

      United Kingdom

	5.	SOLE VOTING POWER
NUMBER OF		
SHARES		0
	6.	SHARED VOTING POWER
BENEFICIALLY		
OWNED BY		2,850,000
EACH	7.	SOLE DISPOSITIVE POWER
REPORTING		
PERSON		0
	8.	SHARED DISPOSITIVE POWER
WITH		
		2,850,000

9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

      2,850,000

10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see
      instructions)

11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     8.6% (1)

12.   TYPE OF REPORTING PERSON (see instructions)

     IN

(1)   The percentage set forth in Row 11 of this Cover Page is based on the 33,203,517 shares of Common Stock (as defined herein) of the Issuer (as defined herein) outstanding as of October 29, 2018, as reported in the Issuer s Form 10-Q filed with the Securities and Exchange Commission on November 2, 2018.

Item 1.

    (a) **Name of Issuer**

Apyx Medical Corporation (f/k/a Bovie Medical Corporation)

    (b) **Address of Issuer s principal executive offices**

5115 Ulmerton Road, Clearwater, FL 33760

Item 2.

    (a) **Name of person filing**

This Amendment No. 3 to the Schedule 13G filed on September 13, 2016 (as amended by Amendment No. 1 thereto filed on February 10, 2017 and Amendment No. 2 thereto filed on February 9, 2018) is being filed on behalf of William Weeks Vanderfelt with respect to the shares of Common Stock, $0.001 par value per share (the   **Common Stock**), of Apyx Medical Corporation, a Delaware corporation (f/k/a Bovie Medical Corporation, the   **Issuer**).

    (b) **Address or principal business office or, if none, residence**

Coralis 44, Azzuri Village 44, Roches Noires, 31201 Mauritius

    (c) **Citizenship**

See Row 4 of the Cover Page.

    (d) **Title of class of securities**

Common Stock, par value $0.001 per share

    (e) **CUSIP No.**

03837C106

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b)   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c)   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d)   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e)   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)   An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(h)   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)   A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);

(k)   Group, in accordance with §240.13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution:

Item 4. Ownership.

The information required by Items 4(a)-(c) is set forth in Rows 5-11 of the Cover Page and is incorporated herein by reference.

Item 5. Ownership of 5 Percent or Less of a Class.

Not applicable.

Item 6. Ownership of More than 5 Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURES

After reasonable inquiry and to the best of the undersigned s knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

DATED: January 18, 2019

By: /s/ WILLIAM WEEKS VANDERFELT
William Weeks Vanderfelt